The role of probiotics in human microecology

Autor: Babich, Ye, Chepurnaya, M

Publikováno v: Annals of Mechnikov's Institute; № 1 (2014); 5-9

Today the number of violations in dysbiotic microflora of the gastrointestinal tract increases. This is a consequence of many factors: the effect of negative environmental factors, the uncontrolled use of antibiotics, reduced adaptive capacity of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=scientific_p::806b191ea405921c8edc8bc8ba1c5642
http://journals.uran.ua/ami/article/view/207869

P011 The diversity of large genomic rearrangements of the CFTR gene in Russian patients with cystic fibrosis

Autor: Petrova, N., Kondratyeva, E., Krasovskiy, S., Adyan, T., Polyakov, A., Zodbinova, A., Melyanovskaya, Y., Kashirskaya, N., Amelina, E., Starinova, M., Voronkova, A., Sherman, V., Chernyak, A., Chepurnaya, M., Filimonova, T., Smirnova, V., Stezhkina, E., Vasilieva, E., Yakovleva, V., Borisov, A., Boychenko, E., Kozlov, A., Odinokova, O., Gembitskaya, T., Kovalev, V., Alimova, I., Baykova, G., Kozyreva, L., Ochirova, N., Mankieva, L., Lakhova, E., Ivakhnenko, E., Trishina, S., Komlev, N., Dyachkova, A., Pyaterkina, O., Shakirova, G., Togochakova, O., Yagubyants, E., Zinchenko, R., Kutsev, S.

Publikováno v: In Journal of Cystic Fibrosis June 2020 19 Supplement 2:S58-S58

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results

Autor: Bradley, Jm, Koker, P, Deng, Q, Moroni Zentgraf, P, Ratjen, F, Geller, De, Elborn, Js, Clements, B, Greville, H, Middleton, P, Serisier, D, van Asperen, P, Dupont, L, Knoop, C, Malfroot, A, Belleguic, C, Chiron, R, Derelle, J, Dominique, S, Dusser, D, Ginies, Jl, Guillot, M, Horeau-Langlard, D, Le Bourgeois, M, Leroy, S, Marguet, C, Munck, A, Pautard, Jc, Reix, P, Uffredi, Ml, Ballmann, M, Bargon, J, Fischer, R, Herth, F, Heuer, He, Griese, M, Kamin, W, Kohlhäufl, M, Nährlich, L, Riethmüller, J, Sorichter, S, Wagner, T, Bennett, L, Crawford, M, Crossley, J, Derry, D, Doull, I, Elborn, J, Everard, M, Groggins, C, Johnson, M, Lee, T, Rayner, R, Reid, A, Smyth, A, Southern, K, Thomas, D, Walshaw, M, Whitehouse, J, Braggion, C, De Rose, V, Gagliardini, R, Minicucci, L, Reijers, M, Tiddens, Ha, O'Carroll, M, Wong, J, Barreto, C, Cardim, P, Loureiro, M, Rocha, H, Vaz, Ml, Asherova, I, Chepurnaya, M, Chuchalin, Ag, Ilkovich, M, Kapranov, N, Neretina, A, Orlov, A, Simonova, O, Ahrens, R, Anbar, R, Biller, J, Carveth, H, Daines, C, Fiel, S, Flume, P, Froh, D, 3rd, Harris J., Howenstine, M, Millard, Dl, Nasr, S, Parker, H, Pian, M, Royall, J, Sabogal, C, Salathe, M, Sannuti, A, Schaeffer, D, Strausbaugh, S, Toder, D, Reyes, S, Whittaker, L, Zanni, R.

Publikováno v: PLoS ONE
Bradley, J M, Koker, P, Deng, Q, Moroni-Zentgraf, P, Ratjen, F, Geller, D E & Elborn, S 2014, ' Testing two different doses of tiotropium Respimat® in cystic fibrosis: Phase 2 randomized trial results ', PLoS ONE, vol. 9, no. 9, e106195, pp. 1-9 . https://doi.org/10.1371/journal.pone.0106195
PLoS ONE, Vol 9, Iss 9, p e106195 (2014)

Background Tiotropium is a once-daily, long-acting anticholinergic bronchodilator with the potential to alleviate airway obstruction in cystic fibrosis. Our objective was to evaluate the efficacy and safety of 2.5 and 5 µg once-daily tiotropium deli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6a0f6fd01cdda96e98323be257e434
http://europepmc.org/articles/PMC4154718